• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Shortened BDLC Regimen Not Noninferior for Drug-Resistant TB

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 22, 2025.

TUESDAY, July 22, 2025 -- For preextensively drug resistant tuberculosis (TB), a shortened bedaquiline, delamanid, linezolid, and clofazimine (BDLC) regimen is not noninferior to longer standard of care, according to a study published online July 16 in The Lancet Respiratory Medicine.

Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted an open-label, noninferiority, randomized phase 3 trial in 10 hospitals involving participants aged 15 years or older who had pulmonary TB with resistance to rifampicin and fluoroquinolones. Participants were randomly assigned to receive BDLC or individualized World Health Organization-recommended longer standard of care (control) in a 2:1 ratio (219 and 105 individuals, respectively). BDLC was administered for nine months for extensive disease and for six months for limited disease.

The researchers found that at week 73, favorable outcome was reached by 87 and 89 percent of the modified intention-to-treat population in the BDLC and control groups, respectively (adjusted risk difference, 0.2 percent; P_{noninferiority} = 0.0051) and by 88 and 93 percent of the per-protocol population (adjusted risk difference, −3.5 percent; P_{noninferiority} = 0.037). Overall noninferiority was not demonstrated. At least one grade 3 or higher adverse event occurred in 68 and 73 percent of participants in the BDLC and control groups, respectively, with eight and two all-cause deaths occurring by week 73 (4 and 2 percent, respectively).

"This shorter regimen is not a surefire cure for everyone," co-senior author Carole D. Mitnick, Sc.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, said in a statement. "The big takeaway is that we might need a more tailored approach to treatment of this kind of resistant TB."

One author disclosed ties to Janssen Pharmaceuticals.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.